INTRODUCTION AND OBJECTIVES: Programmed death ligand-1 (PD-L1), as a promising anti-tumor target, has proved its significant clinical value in many malignancies. However, the expression of PD-L1 in Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and association with clinical outcomes remains unclear. This study amid to investigate the expression of PD-L1 in Xp11.2 RCC and to assess its prognostic value.
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METHODS: Immunohistochemistry was conducted on formalinfixed paraffin-embedded specimens from 36 adult Xp11.2 RCC patients who were histologically confirmed by FISH analysis. Students's t-test and Chi-square test were used to evaluate the relationship between PD-L1 expression and clinicopathological parameters. Cox regression models were used to evaluate the prognostic value of all parameters.
RESULTS: Among 36 assessed Xp11.2 RCC patients, 9 (25.0%) patients showed high expression of PD-L1 and 27 (75.0%) patients showed low PD-L1 expression. High PD-L1 expression was correlated with the presence of advanced tumor stage (P¼0.001), regional lymph node metastasis (P<0.001) and distant metastasis (P<0.001). In the multivariate analysis, N stage (HR: 4.316, P ¼ 0.032), M stage (HR: 16.561, P ¼ 0.009) and high PD-L1 expression (HR: 4.236, P ¼ 0.007) were independent prognostic factors of PFS. Moreover, high PD-L1 expression (HR: 6.479, P ¼ 0.006), along with distant metastasis (HR: 9.215, P ¼ 0.016), was independent prognostic factors after adjusting for covariates.
CONCLUSIONS: High PD-L1 expression is independently associated with tumor progression and predictive of adverse prognosis for Xp11.2 RCC patients. Importantly, our findings may provide a basis for the use of immunotherapy targeting the PD-1/PD-L1 pathway as a potential novel treatment for Xp11.2 RCC patients. METHODS: The study retrospectively enrolled a training set (474 patients) and a validation set (188 patients) with non-metastasis (pT1-4N0M0) ccRCC from two institutional medical centers of China. TIMs was evaluated by immunohistochemical staining of tryptase and its association with clinicopathologic features and prognosis were evaluated.
RESULTS: In ccRCC tissues, TIMs ranged from zero to 103 cells/mm2 and zero to 113 cells/mm2 in the training set and validation set, respectively. TIMs was negatively correlated with tumor size (P < 0.001 and P < 0.001, respectively), pathological T stage (P ¼ 0.005 and P ¼ 0.007, respectively) and Fuhrman grade (P < 0.001 and P < 0.001, respectively). Patients with abundant TIMs infiltration showed significantly longer cancer-specific survival in the training cohort and the validation cohort (P < 0.001 and P < 0.001). Patients with abundant mast cell infiltration showed significantly longer overall survival in the TCGA cohort (P<0.001). Moreover, multivariate analysis identified TIMs as an independent prognostic factor for cancer-specific survival (CSS) and relapse-free survival (RFS). Also, TIMs was significantly correlated with CSS and RFS of the mediate and high risk patients in the training cohort and the validation cohort.
CONCLUSIONS: TIMs density is a powerful independent prognostic factor for CSS and RFS in patients with non-metastasis (pT1-4N0M0) ccRCC.
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